We are dedicated to advancing patient-focused clinical research and drug development for some of today’s most serious neuroscience and pain challenges.
Possessing demonstrated expertise and a wealth of international experience across neurological, psychiatric, and analgesic drug development, we provide innovative clinical research solutions for patients and families facing healthcare challenges that include pediatric and rare indications, and conditions such as Alzheimer’s disease, multiple sclerosis, depression, and chronic pain.
Under the expert guidance of our in-house board-certified neurologists and psychiatrists, we have carried out pivotal trials leading to the approval of 20 drugs for the treatment, prevention, and cure of neurological, psychiatric, and pain disorders.
We gather quality, actionable data, utilize novel analytics to inform clinical decision-making, and apply advanced technologies to better understand the patient experience.
The patient journey – and improved quality of life – is at the forefront of everything that we do.Learn about the studies PRA is conducting with both healthy subjects and patients with various types of acute and chronic pain.
New treatments on the horizon
We are continually striving for new treatment programs for those suffering from a neurodegenerative or neuro-inflammatory condition, as we explore novel designs and leverage vast pools of data to foster innovative approaches for the advancement of future therapeutics.
Conducting diagnostic, preventive, and curative research, we bring significant commitment and experience to every clinical study, with particular expertise in Alzheimer’s disease and related dementias and mild cognitive impairment, Parkinson’s disease, motor neurone disease, and multiple sclerosis.Take a look at how PRA is leading the global fight against Alzheimer’s disease.
Neurodegenerative Research: A Future Mindset
Explore the critical need for research into neurodegenerative disorders, with particular emphasis on the future of clinical development and Alzheimer's research.
Alleviating the pain
We are uniquely equipped to alleviate pain with our state-of-the-art facilities – in addition to our unmatched commitment to quality, in-depth experience studying numerous compounds, and a strong track record in patient retention. All this along with our advanced tools and systems make us industry leaders in analgesic development.
Our experience encompasses post-operative, neuropathic, chronic, and breakthrough pain, as well as research into experimental pain models.
We are at the forefront in Human Abuse Potential (HAP) studies and addiction therapeutics, with extensive research experience with recreational users of opioids, benzodiazepines, stimulants, and cannabinoids. We apply findings from pharmacogenetic testing to aid the discovery of personalized medicine for safer, more effective analgesics.
Our research also encompasses addiction therapeutics. Addiction is a complicated disease for which we seek evidence-based approaches for the treatment of substance-related disorders.Learn about the cognitive and personality characteristics that may make an individual more vulnerable to recreational drug abuse.
Neuroscience and pain study experience over the past five years include:
Central Nervous System clinical development strategies and expertise
Our industry-leading team of neurologists and psychiatrists brings unique expertise and insight to every clinical study. A snapshot of this expertise and strategies employed includes:
Dedicated neuroscience and pain start-up unit for efficient global study activation.
Novel database analytics facilitate strategic country and site selection to expedite clinical studies.
Comprehensive understanding of global variations in standards of care and care settings for neurological and psychiatric conditions.
Proactive strategies to motivate sites and promote patient recruitment in highly competitive indications such as multiple sclerosis and Alzheimer’s disease.
Standardized diagnosis and assessment with special attention to rating, a critical part of most neuroscience and pain studies.
Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Phase 1 Studies in Subjects with Stable Schizophrenia
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in meta-analysis to be as high as 76% (Robinowitz…